Licensing opportunity
The UK biotech Vernalis plc is looking for a new home for a Phase II anti-inflammatory drug, after all rights to the portfolio of matrix metalloproteinase (MMP) inhibitors were handed back by from Merck Serono SA. The compounds were originally part of a licensing agreement between the Vernalis and Serono, dating back to before Merck acquired the Swiss biotech.
The lead compound, V85546 a selective MMP-12 inhibitor, has completed Phase I clinical trials. The compound was returned to Vernalis with a full data package, which includes extensive supporting pharmacology data for a broad range of indications, including chronic obstructive pulmonary disease, acute respiratory distress syndrome and multiple sclerosis.
Vernalis is determining the optimal development programme and is looking for a new collaborative agreement to take the compound into Phase II.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
